Gilead Sciences (GILD) Upgraded at ValuEngine

Share on StockTwits

Gilead Sciences (NASDAQ:GILD) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Tuesday.

GILD has been the subject of a number of other reports. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 6th. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 price target for the company in a report on Thursday, April 19th. Barclays cut their price target on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 2nd. Piper Jaffray Companies started coverage on shares of Gilead Sciences in a report on Wednesday, May 30th. They issued a “buy” rating and a $85.00 price target for the company. Finally, Leerink Swann set a $72.00 price target on shares of Gilead Sciences and gave the company a “market perform” rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, fifteen have given a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences has an average rating of “Buy” and a consensus price target of $88.22.

Shares of Gilead Sciences opened at $71.28 on Tuesday, according to Marketbeat.com. Gilead Sciences has a twelve month low of $64.27 and a twelve month high of $89.54. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.84 and a quick ratio of 2.75. The stock has a market capitalization of $92.11 billion, a price-to-earnings ratio of 8.33, a price-to-earnings-growth ratio of -6.16 and a beta of 1.12.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.19). Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The business had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.40 billion. During the same period in the previous year, the company posted $2.23 earnings per share. Gilead Sciences’s revenue was down 21.8% compared to the same quarter last year. equities research analysts forecast that Gilead Sciences will post 5.75 EPS for the current year.

In other news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $68.13, for a total value of $3,406,500.00. Following the transaction, the director now owns 3,067,762 shares in the company, valued at approximately $209,006,625.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Francis Cogan sold 5,836 shares of the company’s stock in a transaction dated Friday, May 4th. The shares were sold at an average price of $65.09, for a total value of $379,865.24. Following the completion of the transaction, the director now owns 58,455 shares in the company, valued at approximately $3,804,835.95. The disclosure for this sale can be found here. Insiders sold a total of 129,168 shares of company stock worth $9,132,233 in the last quarter. 1.16% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Archford Capital Strategies LLC acquired a new position in Gilead Sciences in the first quarter worth approximately $106,000. Certified Advisory Corp acquired a new position in Gilead Sciences in the fourth quarter worth approximately $133,000. Advisors Preferred LLC acquired a new position in Gilead Sciences in the first quarter worth approximately $140,000. Stelac Advisory Services LLC acquired a new position in Gilead Sciences in the first quarter worth approximately $141,000. Finally, Mckinley Capital Management LLC Delaware increased its holdings in Gilead Sciences by 67.7% in the first quarter. Mckinley Capital Management LLC Delaware now owns 2,130 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 860 shares during the last quarter. Hedge funds and other institutional investors own 77.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply